Renasant Bio is a biopharmaceutical company pioneering disease-modifying oral small molecule treatments for autosomal dominant polycystic kidney disease (ADPKD), the leading genetic cause of end-stage renal failure. Renasant is advancing a pipeline of oral small molecule corrector and potentiator programs that target the underlying biology of ADPKD to restore the function of key proteins to halt disease progression.
| Date | Amount | Type | Investors | Valuation |
|---|---|---|---|---|
| 07/14/25 | $54,500,000 | Seed |
5AM Ventures Atlas Venture OrbiMed Advisors Qiming Venture Partners | undisclosed |
